Cite
HARVARD Citation
Rabe, K. et al. (2019). A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory medicine. pp. 59-66. [Online].